tiprankstipranks
Advertisement
Advertisement

DE:BO1 Stock Latest News

BioCryst announces Japan MHLW marketing approval for Orladeyo
The FlyBioCryst announces Japan MHLW marketing approval for Orladeyo
12d ago
BCRX
BioCryst Earnings Call Highlights Growth And Discipline
PremiumCompany Announcements
BioCryst Earnings Call Highlights Growth And Discipline
21d ago
BCRX
BioCryst price target lowered to $20 from $21 at Wedbush
PremiumThe Fly
BioCryst price target lowered to $20 from $21 at Wedbush
1M ago
BCRX
BioCryst price target lowered to $13 from $14 at RBC Capital
PremiumThe Fly
BioCryst price target lowered to $13 from $14 at RBC Capital
1M ago
BCRX
Stacy Ku Reiterates Buy on BioCryst, Citing Strong Orladeyo Momentum, Durable Growth, and Billion-Dollar HAE Opportunities
PremiumRatings
Stacy Ku Reiterates Buy on BioCryst, Citing Strong Orladeyo Momentum, Durable Growth, and Billion-Dollar HAE Opportunities
1M ago
BCRX
BioCryst reports Q2 EPS 30c, consensus 23c
PremiumThe FlyBioCryst reports Q2 EPS 30c, consensus 23c
1M ago
BCRX
BioCryst Reports Strong Q2 Results, Raises 2026 Guidance
Premium
Company Announcements
BioCryst Reports Strong Q2 Results, Raises 2026 Guidance
1M ago
8K
BCRX
Is BCRX a Buy, Before Earnings?
Premium
Pre-Earnings
Is BCRX a Buy, Before Earnings?
1M ago
BCRX
BioCryst appoints David Jenkins as chief scientific officer
PremiumThe Fly
BioCryst appoints David Jenkins as chief scientific officer
2M ago
BCRX
BioCryst resumed with a Neutral at JPMorgan
PremiumThe Fly
BioCryst resumed with a Neutral at JPMorgan
2M ago
BCRX
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
PremiumThe Fly
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
2M ago
ASND
BCRX
BioCryst price target raised to $14 from $13 at RBC Capital
PremiumThe Fly
BioCryst price target raised to $14 from $13 at RBC Capital
2M ago
BCRX
BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
PremiumRatingsBioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
2M ago
BCRX
BioCryst price target raised to $29 from $27 at Cantor Fitzgerald
Premium
The Fly
BioCryst price target raised to $29 from $27 at Cantor Fitzgerald
2M ago
BCRX
Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target
Premium
Ratings
Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target
2M ago
BCRX
BioCryst Advances Rare Disease Pipeline Amid Cost Controls
PremiumCompany Announcements
BioCryst Advances Rare Disease Pipeline Amid Cost Controls
2M ago
8K
BCRX
BioCryst to discontinue internal discovery programs, close Alabama facility
PremiumThe Fly
BioCryst to discontinue internal discovery programs, close Alabama facility
2M ago
BCRX
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
2M ago
CGC
IRE
BioCryst Shareholders Approve Expanded Equity Incentive Plan
PremiumCompany Announcements
BioCryst Shareholders Approve Expanded Equity Incentive Plan
3M ago
8K
BCRX
BioCryst to present new Orladeyo data at EAACI
PremiumThe FlyBioCryst to present new Orladeyo data at EAACI
3M ago
BCRX
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks
Premium
Company Announcements
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks
4M ago
BCRX
BioCryst price target raised to $28 from $25 at Citizens
Premium
The Fly
BioCryst price target raised to $28 from $25 at Citizens
4M ago
BCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >